Skip to main content

Advertisement

SpringerLink
Log in

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9–17 %), stable weight (47–64 %), and gained weight (27–36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dixon JK, Moritz DA, Baker FL (1978) Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum 5(3):5–7

    CAS  PubMed  Google Scholar 

  2. Knobf MK, Mullen JC, Xistris D, Moritz DA (1983) Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 10(2):28–33

    CAS  PubMed  Google Scholar 

  3. Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd NF (1985) Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5(2):195–200

    Article  CAS  PubMed  Google Scholar 

  4. Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294

    Article  CAS  PubMed  Google Scholar 

  5. Fedele P, Orlando L, Schiavone P et al (2014) BMI variation increases recurrence risk in women with early-stage breast cancer. Future Oncol 10(15):2459–2468

    Article  CAS  PubMed  Google Scholar 

  6. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24(10):2506–2514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nechuta S, Chen WY, Cai H et al (2016) A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138(9):2088–2097

    Article  CAS  PubMed  Google Scholar 

  8. Sinicrope FA, Dannenberg AJ (2011) Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 29(1):4–7

    Article  PubMed  Google Scholar 

  9. Bradshaw PT, Ibrahim JG, Stevens J, Cleveland RJ, Abrahamson PE et al (2012) Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23(2):320–327

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635

    Article  PubMed  Google Scholar 

  12. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML (2015) Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 107(12):djv275

    Article  PubMed  Google Scholar 

  13. Caan BJ, Emond JA, Su HI et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 30(13):1492–1497

    Article  PubMed  PubMed Central  Google Scholar 

  14. Young A, Weltzien E, Kwan M, Castillo A, Caan B, Kroenke CH (2014) Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors. J Cancer Surviv 8(4):539–547

    Article  PubMed  PubMed Central  Google Scholar 

  15. Forsythe LP, Alfano CM, George SM et al (2013) Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior. Breast Cancer Res Treat 137(2):617–630

    Article  PubMed  Google Scholar 

  16. Befort CA, Austin H, Klemp JR (2011) Weight control needs and experiences among rural breast cancer survivors. Psychooncology 20(10):1069–1075

    Article  PubMed  Google Scholar 

  17. Voskuil DW, van Nes JG, Junggeburt JM, van de Velde CJ, van Leeuwen FE, de Haes JC (2010) Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann Oncol 21(10):2094–2101

    Article  CAS  PubMed  Google Scholar 

  18. Schmitz KH, Neuhouser ML, Agurs-Collins T et al (2013) Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst 105(18):1344–1354

    Article  PubMed  PubMed Central  Google Scholar 

  19. Keegan TH, Kurian AW, Gali K et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105(5):938–946

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kroenke CH, Michael YL, Shu XO, Poole EM (2016) Post-diagnosis social networks, and lifestyle and treatment factors in the After Breast Cancer Pooling Project. Psychooncology. doi:10.1002/pon.4059

    PubMed  Google Scholar 

  21. Makari-Judson G, Braun B, Jerry DJ, Mertens WC (2014) Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Onc. 5(3):272–282

    Article  Google Scholar 

  22. Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–518

  23. Surveillance Epidemiology and End Results (SEER) (2016) Breast cancer: SEER fact sheets. National Cancer Institute. 2016. http://seer.cancer.gov/statfacts/html/breast/html. Accessed 02 Aug 2016

  24. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1899–1905

    Article  PubMed  Google Scholar 

  25. Benz CC (2008) Impact of aging on the biology of breast cancer. Crit Rev Oncog Hematol 66(1):65–74

    Article  Google Scholar 

  26. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ et al (2015) Breast cancer, version 1.2016. J Natl Compr Canc Netw 13(12):1475–1485

    PubMed  Google Scholar 

  27. Taylor WC, Muss HB (2010) Recent advances: adjuvant therapy for older women with breast cancer. Cancer J 16(4):289–293

    Article  PubMed  Google Scholar 

  28. Eisen A, Fletcher GG, Gandhi S et al (2015) Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 22(Suppl 1):S67–S81

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Burstein HJ, Griggs JJ, Prestrud AA, Temin S (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 6(5):243–246

    Google Scholar 

  30. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271

    Article  CAS  PubMed  Google Scholar 

  31. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134(2):727–734

    Article  CAS  PubMed  Google Scholar 

  33. Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917

    Article  CAS  PubMed  Google Scholar 

  34. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542

    Article  CAS  PubMed  Google Scholar 

  35. Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940

    Article  CAS  PubMed  Google Scholar 

  37. van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331

    Article  PubMed  Google Scholar 

  38. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19(10):1319–1328

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. 132(2):1107–1118

    CAS  Google Scholar 

  40. Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ (2012) Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climacteric 15(4):339–349

    Article  CAS  PubMed  Google Scholar 

  41. Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Zivian MT, Salgado B (2008) Side effects revisited: women’s experiences with aromatase inhibitors. Breast Cancer Action, San Francisco

    Google Scholar 

  43. Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B et al (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128(2):553–561

    Article  CAS  PubMed  Google Scholar 

  44. Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498

    Article  CAS  PubMed  Google Scholar 

  45. Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57

    Article  Google Scholar 

  46. Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast. 13(5):363–368

    Article  CAS  PubMed  Google Scholar 

  47. Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K (2015) Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer. Cancer Epi Biomarkers Prev 24(8):1262–1269

    Article  CAS  Google Scholar 

  48. Mortimer J, Behrendt CE (2013) Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis. J Palliat Med 16(9):1130–1134

    Article  PubMed  Google Scholar 

  49. Sedjo RL, Hines LM, Byers T et al (2013) Long-term weight gain among Hispanic and non-Hispanic White women with and without breast cancer. Nutr Cancer 65(1):34–42

    Article  PubMed  Google Scholar 

  50. Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer–effect of tamoxifen. Breast Cancer Res Treat 22(2):129–132

    Article  CAS  PubMed  Google Scholar 

  51. Gu K, Chen X, Zheng Y et al (2010) Weight change patterns among breast cancer survivors: results from the Shanghai breast cancer survival study. Cancer Causes Control 21(4):621–629

    Article  PubMed  Google Scholar 

  52. Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the Women’s healthy Eating and Living (WHEL) study. Breast Cancer Res Treat 105(2):177–186

    Article  PubMed  Google Scholar 

  53. Francini G, Petrioli R, Montagnani A et al (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95(2):153–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Sedjo R, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. Cancer Surv 8(3):410–418

    Article  Google Scholar 

  55. Reddy S, Sadim M, Li J et al (2013) Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Br J Cancer 109(4):872–881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Han HS, Lee KW, Kim JH et al (2009) Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat 114(1):147–153

    Article  CAS  PubMed  Google Scholar 

  57. Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129

    CAS  PubMed  Google Scholar 

  58. Makari-Judson G, Judson CH, Mertens WC (2007) Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. Breast 13(3):258–265

    Article  Google Scholar 

  59. Chen X, Lu W, Gu K et al (2011) Weight change and its correlates among breast cancer survivors. Nutr Cancer 63(4):538–548

    Article  PubMed  PubMed Central  Google Scholar 

  60. Irwin ML, McTiernan A, Baumgartner RN, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782

    Article  PubMed  PubMed Central  Google Scholar 

  61. Kumar NB, Allen K, Cantor A et al (1997) Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat 44(2):135–143

    Article  CAS  PubMed  Google Scholar 

  62. Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 13(5):363–368

    Article  CAS  PubMed  Google Scholar 

  63. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542

    Article  CAS  PubMed  Google Scholar 

  64. Su H, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57

    Article  Google Scholar 

  66. McGowan P, Perry M, Hewett J, Ge B, Sanfilippo K (2006) Weight gain in breast cancer patients: tamoxifen versus anastrozole. J Clin Oncol 24(18S (June 20 Suppl)):10544

    Google Scholar 

  67. Lin CJ, DeRoo LA, Jacobs SR, Sandler DP (2012) Accuracy and reliability of self-reported weight and height in the Sister Study. Public health Nutr 15(6):989–999

    Article  PubMed  Google Scholar 

  68. Weaver TW, Kushi LH, McGovern PG et al (1996) Validation study of self-reported measures of fat distribution. Int J Obes Relat Metab Disord 20(7):644–650

    CAS  PubMed  Google Scholar 

  69. Gillum RF, Sempos CT (2005) Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J 4:27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lim U, Wilkens LR, Albright CL, Novotny R, Le Marchand L, Kolonel LN (2013) University of Hawai’i Cancer Center Connection: bias in self-reported anthropometry in relation to adiposity and adulthood weight gain among postmenopausal Caucasian and Japanese American Women. Hawai’i J Med Public Health 72(12):445–449

    Google Scholar 

  71. Bradshaw PT, Nichols HB, Caan BJ (2016) RE: weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 108(4):djw023

    Article  PubMed  Google Scholar 

  72. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409

    Article  PubMed  PubMed Central  Google Scholar 

  73. Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW (2009) The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45:119–126

    Article  CAS  PubMed  Google Scholar 

  74. Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883

    Article  PubMed  Google Scholar 

  75. Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CHG, van Laarhoven HWM (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer. Cancer Nurs 1–8

  76. Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH (2014) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 20(1):22–28

    Article  CAS  PubMed  Google Scholar 

  77. Kim SH, Cho YU, Kim SJ (2013) Weight gain and its correlates among breast cancer survivors. Asian Nurs Res 7(4):161–167

    Article  Google Scholar 

  78. DeSantis CE, Lin CC, Mariotto AB et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–257

    Article  PubMed  Google Scholar 

  79. Colleoni M, Gelber S, Goldhirsch A et al (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13–93. J Clin Oncol 24(9):1332–1341

    Article  CAS  PubMed  Google Scholar 

  80. Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917

    Article  CAS  PubMed  Google Scholar 

  81. Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331

    Article  PubMed  Google Scholar 

  83. Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10027):857–865

    Article  CAS  PubMed  Google Scholar 

  84. Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107–1118

    Article  CAS  PubMed  Google Scholar 

  85. Glaus A, Boehme C, Thürlimann B et al (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17(5):801–806

    Article  CAS  PubMed  Google Scholar 

  86. McInnes J, Knobf MT (2001) Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nurs Forum 28(4):675–684

    CAS  PubMed  Google Scholar 

  87. Love RR, Hutson PR, Havighurst TC, Cleary JF (2005) Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin Cancer Res 11(4):1500–1503

    Article  CAS  PubMed  Google Scholar 

  88. Sedjo RL, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. J Cancer Surviv 8(3):410–418

    Article  PubMed  PubMed Central  Google Scholar 

  89. Basaran G, Turhal NS, Cabuk D et al (2011) Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol 28(2):409–415

    Article  CAS  PubMed  Google Scholar 

  90. Vagenas D, DiSipio T, Battistutta D et al (2015) Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15(1):28 (Epub ahead of print)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by funding from the University Cancer Research Fund of the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.

Author information

Authors and Affiliations

  1. School of Medicine, University of North Carolina at Chapel Hill, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA

    K. A. Nyrop, G. R. Williams & H. B. Muss

  2. School of Medicine, University of North Carolina at Chapel Hill, Haifa, Israel

    S. S. Shachar

Authors
  1. K. A. Nyrop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. R. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. B. Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. S. Shachar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. A. Nyrop.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nyrop, K.A., Williams, G.R., Muss, H.B. et al. Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?. Breast Cancer Res Treat 158, 203–217 (2016). https://doi.org/10.1007/s10549-016-3874-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3874-0

Keywords

Search

Navigation